An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial
Circulation
NOVEMBER 23, 2023
There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point. 3.30]) and subacute definite or probable stent thrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26–9.23]) mg/day) monotherapy or to DAPT with aspirin (81–100 mg/day) and prasugrel (3.75
Let's personalize your content